ACC.25 – In the phase 3 REVERSE-IT trial, the investigational monoclonal antibody bentracimab effectively and safely reversed the antiplatelet effect of ticagrelor in patients undergoing urgent surgery or with major bleeding.
Ticagrelor antidote restores platelet function in phase 3 study
ACC.25 – In the phase 3 REVERSE-IT trial, the investigational monoclonal antibody bentracimab effectively and safely reversed the antiplatelet effect of ticagrelor in patients undergoing urgent surgery or with major bleeding.
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Educational information
This video was recorded during the ACC.25 Scientific Session Chicago, IL, USA.
Faculty
Deepak Bhatt, MD is Director of Mount Sinai Heart, New York, NY, USA. He also is Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai in New York, NY, USA.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 1 April 2025
The information and data provided in this program were updated and correct at the time of its development, but may be subject to change.
Recommended
Details
Presenters
Overview
ACC.25 – In the phase 3 REVERSE-IT trial, the investigational monoclonal antibody bentracimab effectively and safely reversed the antiplatelet effect of ticagrelor in patients undergoing urgent surgery or with major bleeding.
Educational information
This video was recorded during the ACC.25 Scientific Session Chicago, IL, USA.
Faculty
Deepak Bhatt, MD is Director of Mount Sinai Heart, New York, NY, USA. He also is Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai in New York, NY, USA.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 1 April 2025
The information and data provided in this program were updated and correct at the time of its development, but may be subject to change.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Cardiology
Phase 3 study results of plozasiran in patients with FCS
<p>Phase 3 study results of plozasiran in patients with FCS</p>
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
<p>FCS and SHTG: Are We Meeting the Need?</p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
MinuteCE®
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
1.00 credits
<p>Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D</p>
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
<p>Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial</p>
Cardiology
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
<p><span data-teams="true">Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial</span> </p>
Cardiology
NYHA FC and Finerenone Response: Clinical Trial Insights
<p><span data-contrast="auto" xml:lang="EN-US">NYHA FC and Finerenone Response: Clinical Trial Insights</span><span data-ccp-props='{"134245417":false,"335559739":0}'> </span></p>
ACC Action Center
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
<p>Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?